BACKGROUND: Up to 30% of infants may be HIV-exposed noninfected (ENI) in countries with high HIV prevalence, but the impact of maternal HIV on the child's health remains unclear. METHODS: One hundred fifty-eight HIV ENI and 160 unexposed (UE) Mozambican infants were evaluated at 1, 3, 9, and 12 months postdelivery. At each visit, a questionnaire was administered, and HIV DNA polymerase chain reaction and hematologic and CD4/CD8 determinations were measured. Linear mixed models were used to evaluate differences in hematologic parameters and T-cell counts between the study groups. All outpatient visits and admissions were registered. ENI infants received cotrimoxazol prophylaxis (CTXP). Negative binomial regression models were estimated to compare incidence rates of outpatient visits and admissions. RESULTS: Hematocrit was lower in ENI than in UE infants at 1, 3, and 9 months of age (P = 0.024, 0.025, and 0.012, respectively). Percentage of CD4 T cells was 3% lower (95% confidence interval: 0.86 to 5.15; P = 0.006) and percentage of CD8 T cells 1.15 times higher (95% confidence interval: 1.06 to 1.25; P = 0.001) in ENI vs. UE infants. ENI infants had a lower weight-for-age Z score (P = 0.049) but reduced incidence of outpatient visits, overall (P = 0.042), diarrhea (P = 0.001), and respiratory conditions (P = 0.042). CONCLUSIONS: ENI children were more frequently anemic, had poorer nutritional status, and alterations in some immunologic profiles compared with UE children. CTXP may explain their reduced mild morbidity. These findings may reinforce continuation of CTXP and the need to understand the consequences of maternal HIV exposure in this vulnerable group of children.
BACKGROUND: Up to 30% of infants may be HIV-exposed noninfected (ENI) in countries with high HIV prevalence, but the impact of maternal HIV on the child's health remains unclear. METHODS: One hundred fifty-eight HIV ENI and 160 unexposed (UE) Mozambican infants were evaluated at 1, 3, 9, and 12 months postdelivery. At each visit, a questionnaire was administered, and HIV DNA polymerase chain reaction and hematologic and CD4/CD8 determinations were measured. Linear mixed models were used to evaluate differences in hematologic parameters and T-cell counts between the study groups. All outpatient visits and admissions were registered. ENI infants received cotrimoxazol prophylaxis (CTXP). Negative binomial regression models were estimated to compare incidence rates of outpatient visits and admissions. RESULTS: Hematocrit was lower in ENI than in UE infants at 1, 3, and 9 months of age (P = 0.024, 0.025, and 0.012, respectively). Percentage of CD4 T cells was 3% lower (95% confidence interval: 0.86 to 5.15; P = 0.006) and percentage of CD8 T cells 1.15 times higher (95% confidence interval: 1.06 to 1.25; P = 0.001) in ENI vs. UE infants. ENI infants had a lower weight-for-age Z score (P = 0.049) but reduced incidence of outpatient visits, overall (P = 0.042), diarrhea (P = 0.001), and respiratory conditions (P = 0.042). CONCLUSIONS: ENI children were more frequently anemic, had poorer nutritional status, and alterations in some immunologic profiles compared with UE children. CTXP may explain their reduced mild morbidity. These findings may reinforce continuation of CTXP and the need to understand the consequences of maternal HIV exposure in this vulnerable group of children.
Authors: Pui-Ying Iroh Tam; Matthew O Wiens; Jerome Kabakyenga; Julius Kiwanuka; Elias Kumbakumba; Peter P Moschovis Journal: Pediatr Infect Dis J Date: 2018-10 Impact factor: 2.129
Authors: Sozinho Acácio; Jennifer R Verani; Miguel Lanaspa; Tarayn A Fairlie; Tacilta Nhampossa; Maria Ruperez; Pedro Aide; Brian D Plikaytis; Charfudin Sacoor; Eusebio Macete; Pedro Alonso; Betuel Sigaúque Journal: Int J Infect Dis Date: 2015-05-14 Impact factor: 3.623
Authors: Kathleen Powis; Shahin Lockman; Laura Smeaton; Michael D Hughes; Wafaie Fawzi; Anthony Ogwu; Sikhulile Moyo; Erik van Widenfelt; Julia von Oettingen; Joseph Makhema; Max Essex; Roger L Shapiro Journal: Pediatr Infect Dis J Date: 2014-11 Impact factor: 2.129
Authors: Herbert Longwe; Kamija S Phiri; Nyanyiwe M Mbeye; Thandile Gondwe; Kondwani C Jambo; Wilson L Mandala Journal: BMC Immunol Date: 2015-08-28 Impact factor: 3.615
Authors: Neema M Kayange; Luke R Smart; Jennifer A Downs; Mwanaisha Maskini; Daniel W Fitzgerald; Robert N Peck Journal: PLoS Negl Trop Dis Date: 2015-01-22